一个全面的模型来评估和分类患有血栓性微血管病的患者:TMA-INSIGHT得分
Vanessa Vilani Addad1, Lilian Monteiro Pereira Palma2, Maria Helena Vaisbich3
1Department of Internal Medicine - UNESP, Univ Estadual Paulista, Rubião Jr, s/n, Botucatu/SP, 18618-687, Brazil.
Thrombosis journal
|November 23, 2023
概括
血栓微血管病变 (TMA) 是一种复杂的综合征. 这项研究开发了一个预测算法,TMA-INSIGHT得分,准确地分类TMA亚型,其次要条件是最常见的原因.
科学领域:
- 血液学 血液学 血液学
- 腎臟病學 (nephrology) 是一種醫學.
- 内部医学 内部医学
背景情况:
- 血栓式微血管病变 (TMA) 是一种由贫血,血栓细胞减小和器官损伤定义的临界综合征,具有多种潜在原因.
- 对TMA病因的准确分类对于有效的患者管理和治疗策略至关重要.
研究的目的:
- 开发和验证一种算法来分类血栓性微血管病变 (TMA) 亚型,称为TMA-INSIGHT评分.
- 确定TMA及其特定表型的关键临床和生化预测因素.
主要方法:
- 一项回顾性队列研究分析了在一个中心住院的TMA患者 (2012-2021年).
- 患者被分为八组:感染,恶性高血压,移植相关,恶性瘤,与怀孕相关,血栓性血栓性缺血性紫外线 (TTP),Shiga毒素介导的血清性尿素综合征 (STEC-HUS) 和非典型的血清性尿素综合征 (aHUS).
- 使用临床数据,实验室结果和平均动脉压,训练了一种机器学习模型 (LightGBM).
主要成果:
- 该研究分析了2407例TMA病例,其次性TMA占诊断的97.5%.
- 轻GBM模型实现了高性能,精度为0.979,多类ROC-AUC为0.966.
- 模型预测对常见的TMA类最准确,对aHUS和STEC-HUS分类的信心略低.
结论:
- 二次性疾病是TMA的主要原因.
- 开发的模型有效地预测了TMA,并使用并发症,相关疾病和平均动脉压来描述其表型特征.
- 这代表了TMA的新型多类预测模型,包括初级和二级病因.
相关概念视频
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.


